KR20030025975A - Skin immune modulating composition containing magnolia extracts as active ingredients - Google Patents

Abstract

PURPOSE: A composition containing an extract of Lycii Fructus having immunoregulatory activity is provided which is effective in improvement of atopic dermatitis, skin rash, contact dermatitis, diaper radish or the like. CONSTITUTION: Lycii Fructus is added 1 to 15 times with a solvent, extracted at 50 to 95deg.C for 1 to 20hr in an extractor attached with a cooling condenser or soaked at 5 to 45deg.C for 1 to 15 days and then filtered with filter cloth. Thereafter, the filtrate is concentrated under reduced pressure and then dissolved in 1,3-butylene glycol to give a dried residue of 2%. For an example, 1kg Lycii Fructus is soaked in 5kg ethanol at 30deg.C for 1 week, filtered with a filter cloth of 300meshes and concentrated at 70deg.C to produce 56.5g Lycii Fructus extract.

Description

Skin immune modulating composition containing magnolia extracts as active ingredients

The present invention relates to a composition to which the myth extract is applied to ameliorate and cure skin diseases resulting from imbalance of skin immune conditions such as atopic dermatitis, skin flare, and skin itching.

Allergic symptoms closely related to atopic dermatitis, allergic dermatitis, urticaria, etc. are known to belong to type I allergy mainly mediated by immunoglobulin E (IgE) antibodies. We will focus on atopic dermatitis, the most serious form of immune response to type 1 allergy. Atopic dermatitis is a recurrent chronic dermatitis with severe pruritus (itching) and it is estimated that 10 to 20% of the world's population suffer from it. In addition, the prevalence of atopic dermatitis continues to rise in recent decades due to the increase of allergens causing airborne allergy due to environmental pollution and the increase of conditions for forming dry skin. In addition, atopic patients are rapidly increasing due to the drying environment and deprivation of early external antigen exposure opportunities due to the spread of apartment environment.

Atopic patients have urticaria response to a large number of antigens when they perform skin tests on protein antigens such as house dust mites, animal hair, pollen, and food. Within a few hours, immediate reactions such as anaphylactic shock, rashes, hematologic edema, wheezing and shortness of breath, nasal congestion, runny nose, sneezing, conjunctival hyperemia and swelling, vomiting, diarrhea and abdominal pain may occur. And it occurs well in the mesentery film, and these characteristics have the characteristic of appearing in the family.

Clinically, atopic dermatitis is characterized by a relatively characteristic skin lesion and distribution according to the age of the patient. The atopic dermatitis can be divided into three stages: infancy, childhood, puberty, and adulthood. In infancy from 2 to 3 months of age when atopic dermatitis begins, atopic dermatitis is red, wooly, oily and crust on the head, face and torso area. It appears as a lesion that forms the back. In children after 3 years of age until puberty, not only dry skin lesions such as papules, lichenification, scale, pigmentation, etc. are found in flexures such as arms, legs, wrists, and ankles. Symptoms such as lichen tendonization of the forehead, redness and tearing around the eyes, and cracks and peeling of the skin around the ears are often accompanied. In puberty and adulthood, lesions such as papules, scales, pigmentation, thyroiditis, and nodules appear in the head, face, neck, torso, limbs and limbs. These atopic dermatitis symptoms usually improve with age, but may last until adulthood.

Atopy is broadly interpreted as a kind of skin immune response. This skin immune response is played by Langelhans cells in the epidermal tissue of the skin. This cell functions as an antigen presenting cell in its peripheral position. In other words, it is responsible for producing and providing antigens for T lymphocytes. Provision of the antigen involves the interaction between the second class of molecules of the major histologic synthetic complex (HLA-DR) expressed by Langelhans cells and the T receptor of CD4 + lymphocytes. During the early stages of immune sensitization, antigens are managed by Langelhans cells in the epidermis and are immunogenic converted. The appearance of antigens for T lymphocytes in the ganglion occurs through the interaction between HLA-DR-immunogenic peptide, a complex on the surface of Langelhans cells, and the T receptor of CD4 + lymphocytes.

Mixed lymphoid epithelial cultures (MLECs) measure the immunomodulatory properties of substances that can control the immunological equilibrium of the skin by measuring the proliferation of lymphocytes induced by allogeneic epithelial cells that provide antigens with or without treatment. It can be one model that makes it possible to measure.

Antiallergic activity is found on keratinocytes and macrophages. Macrophages are particularly beneficial because they are present at the skin level, which regulates not only local inflammatory responses but also immune responses through their ability to provide their antigens and to produce the majority of cytokines that regulate local immunity. to be. These macrophages can also immobilize various types of cells (monocytes, neutrophils, eosinophilic leukocytes, and T lymphocytes) as needed, in connection with the circulatory system which can increase the nonspecific defenses of the tissue of interest. Included.

Recently, due to advances in the study of the skin barrier as well as the skin immunology, skin dryness due to the loss of moisture in the skin due to the failure of the skin barrier has been recognized as an important condition of atopic dermatitis. The skin of atopic dermatitis patients maintains moisture in the skin and prevents the formation of a protective lipid layer because the amount of ceramide that fills the keratinocytes of the outermost stratum corneum decreases compared to normal people. There is a problem with the skin barrier function that protects the skin. Dry skin caused by skin barrier failure facilitates the penetration of external irritants or allergens into the skin and responds to keratinocytes present in the epidermis in response to inflammatory reaction-related cytokines (eg TNF-alpha, Interleukin-1) Non-allergic inflammatory reactions and eczema occur, or antigen-antibody reactions in response to Langelhans cells, which are skin immune cells, increase the amount of antibody called IgE in the serum and In people with poor skin barriers, they may eczema by scratching because of itching. Recently, IgE is known to cause a direct eczema reaction. In other words, antigen-antibody reactions between allergens (such as house dust mites) and IgE cause the production and release of cytokines in mast cells and eczema with lymphocytes and eosinophils.

In order to improve such atopic dermatitis, ceramides that restore skin barrier; essential fatty acids; lipid complexes of cholesterol are applied by methods such as application (or Korean Patent Laid-Open Publication No. 2001-0044622), oral administration of antihistamines to prevent itching, and anti The application of steroids for inflammation is commonly used and the use and application of gammalinolenic acid, which is an essential fatty acid (Epogam (Hanpok Medicine), Korean Patent Publication 2000-0046633), Oligosaccharide for improving skin immune status (Korean Patent Publication) 2000-0029754) and the application of ginkgo biloba extract (Korean Patent Publication 1999-0076619), etc., but there is no patent applied to this myth extract, the present inventors have confirmed the application of the skin immunization function of the myth extract As an atopic dermatitis, it is proposed as a skin immune condition improver.

The ultimate improvement of atopic skin is based on the repair of the stale skin barrier, and the related research has been progressed as described above. Now, it is well known that lipid complexes containing ceramide are ineffective due to atopic skin or dermatitis. Although it is used as a treatment for damaged skin, a more fundamental approach is called immunomodulation. Itching and allergic reactions can worsen skin conditions without controlling the immune status of atopic or dermatitis patients.

However, currently, medicines used as immunomodulators are used cycloclosporin, FK506, but atopic dermatitis such as atopic dermatitis is not used due to cost limitations, and steroid products are still mostly used as external skin preparations.

The present inventors have found that the mythic extract has an immunomodulatory activity and provides an external application for skin, including the same, including a lipid complex containing ceramide, and applied to atopic dermatitis, such as itching and skin rash. To alleviate allergies, etc.

The present invention relates to a cosmetic composition for regulating skin immunity such as atopic skin improvement, skin rash improvement, skin itching improvement, etc., which contains a myth extract (extracted with water or an organic solvent or a mixture of water and an organic solvent).

Shin-Ihwa refers to the unflowered Magnolia kobus DC. Or Magnolia denudata Desr. Flower buds. Its length is 2cm in the shape of a pencil and the outside is blackish brown with a fragrant scent. Xinhua contains essential oils, citral, moistol and cinnaol, and has been used since ancient times for blemishes, freckles, pigmentation, purulent skin and itchy skin.

In the present invention, Xinhua is a mixture of water, acetone, ethyl acetate, diethyl ether, benzene, chloroform, hexane, and lower alcohols having 1 to 4 carbon atoms as an extraction solvent in Xinhua (unflowered magnolia buds). Add 1 to 15 times the dry weight and extract by heating at 50 ~ 95 ℃ for 1 ~ 20 hours in an extractor equipped with a cooling capacitor to prevent evaporation of the active ingredient or by dipping at 5 ~ 45 ℃ for 1 ~ 15 days Extract The obtained extract was filtered through a filter cloth, concentrated under reduced pressure, and then dispersed and dissolved in 1,3 butylene glycol so that the dry residue became 2%, to obtain the myth extract of the present invention. In detail, the sample used in Examples 2 to 4 and Experimental Examples 1 to 3 was obtained using Example 1 below, but the production method of the larvae extract is not limited to Example 1.

Example 1

1 kg of magnolia buds were soaked in 5% in 70% ethanol, extracted for 1 week at 30 ° C., filtered through 300 mesh filter cloth, and dried by rotary evaporator at 70 ° C. to obtain 56.5 g, which was 1.3 butyl to a 2% weight concentration. It was dissolved in lene glycol and used in the experiments and implementation of the present invention.

Example. 2-Example. 5

Raw material name Example 2 Example 3 Example 4 Example 5 Stearic acid 2.0 2.0 2.0 2.0 Stearyl alcohol 3.0 3.0 3.0 3.0 1,3-butylene glycol 5.0 5.0 5.0 5.0 Monostearate Glycol 4.0 4.0 4.0 4.0 Potassium hydroxide 0.1 0.1 0.1 0.1 Purified water 83.9 82.9 81.9 83.9 Ceramide - 1.0 1.0 - Lecithin 1.0 1.0 1.0 1.0 cholesterol 1.0 1.0 1.0 1.0 Xinhua Extract - - 1.0 1.0

The oil and water components are heated to 75 ° C., and then emulsified using a homogenizer in a cream mixer, followed by degassing, filtration and cooling. The cream compositions of Examples 2 to 5 are prepared in a conventional manner. Prepared.

Experimental Example 1 Efficacy test for improving atopic skin.

Example 2 In order to confirm the atopic dermatitis alleviation and treatment effect on the cream composition prepared in 2 to 5 to 20 patients of refractory atopic dermatitis from 6 to 18 years old, in the untreated group, Examples 2 to 4, etc. Four groups of four students per group were applied for four weeks, and the subjects were evaluated based on the following criteria and averaged. In this evaluation, the average score of 3.5 or above was judged to be effective for atopic dermatitis and the results are shown in the table below. 1 is shown.

1 point | piece: It became worse. 2 points | pieces: No effect. 3 points | points: It seems to be slightly relaxed but it does not feel well.

4 points | pieces: The relief is certainly felt. 5 points: It improved very much.

Table 1 Clinical Effect of Atopic Skin Improvement

No treatment Slashing Example 2 Example 3 Example 4 Example 5 5 days later 32.3 28.6 25.1 23.2 24.8 10 days later 30.7 23.2 21.8 18.4 20.7 After 20 days 31.5 22.2 19.9 15.3 18.2

Including the ceramide and mythic extracts in the above experiments showed an excellent effect.

And in order to confirm the results more clearly, an experiment was performed to evaluate the skin barrier repair function through the percutaneous moisture loss measurement. Experimental Example 2

Experimental Example 2: Measurement test of the degree of transdermal moisture loss (TEWL)

Experimental Example 1 Atopic skin lesions of the subjects participating in Example 1 were measured using a Tewameter TM210 (Courage + Khazaka, Germany) before, 5, 10, and 20 days after applying the products of 2-5. . The measurement results are shown in Table 2 below (values are average numbers of four people).

Table 2 Changes in transdermal moisture loss according to the progress of treatment in Examples 2 to 5 (unit: g / m ² h)

Example 2 Example 3 Example 4 Example 5 Average score 3.0 3.9 4.6 4.4

Example 2 It was judged that the effect of lecithin, which is the basis of creams 2 to 5, was somewhat effective, and the effect part by the mythic extract was certainly confirmed.

The present invention relates to the use of mythic extracts used in skin immunity-related diseases such as atopic dermatitis, skin rash and contact dermatitis. It can be used for the improvement of skin rash, skin pruritus, including atopic dermatitis, contact dermatitis, diaper rash, and the like.

Claims (2)

Skin external preparation composition for skin immunity control comprising extract of [Flower of Magnolia kobus DC or Magnolia denudata Desr.] According to claim 1, skin immunity control means use for the treatment or prevention of diseases such as atopic dermatitis, skin pruritus, psoriasis, dermatitis, skin dryness, rash, skin redness.